Abstract:Expression of programmed death ligand 1 (PD-L1) is rendered a possible biomarker for immunotherapy targeting programmed death protein 1 (PD1) and PD-L1. Durable clinical responses have been demonstrated in patients with squamous cell carcinoma (SqCC) of the lung. Tumor infiltrating lymphocytes (TILs) are also regarded important players in immunomodulating therapies. Still, there is much uncertainty regarding the expression of the markers and associated tumor characteristics. We aimed to assess the prognostic impact and heterogeneity of PD-L1 expression across two antibodies, in conjunction with TILs, in SqCC of the lung. PD-L1 expression was investigated on a tissue microarray (TMA) of pulmonary SqCC using immunohistochemistry and two different clones (SP142, E1L3N). The cohort comprised all consecutive patients with primary resected pulmonary SqCC, without previous SqCC of other sites, diagnosed 2000-2013 at the Institute of Pathology, University of Bern. Epithelial expression of PD-L1 in primary tumors (n=372) and mediastinal lymph node (LN) metastases (n=27) was evaluated across 8 TMA cores per tumor using the following increment intervals: 0%; 1%; 5%; 10%; 20%; 30%, 50%. Intratumoral and intraepithelial infitrates of CD8+ T lymphocytes were determined. Results were compared with clinic-pathologic parameters including tumor related survival. The staining results correlated significantly between the two antibodies (r=0.822; p<0.001) with the best congruence for tumors with ≤1% or ≥30% positivity. These tumors had also very homogenous staining results across all TMA cores, indicating low levels of intratumoral heterogeneity, in contrast to tumors with 1-30% PD-L1 positivity (p<0.001 both antibodies). Stainings correlated significantly between primary tumors and LN metastases (p<0.001 both antibodies). High PD-L1 expression correlated with intratumoral and intraepithelial CD8+ lymphocyte counts in primaries (p<0.001 both antibodies). PD-L1 expression was not significantly associated with pT or pN staging. High PD-L1 expression was associated with shorter tumor related survival. Cut-offs with the best prognostic discrimination were 30% positivity for SP142 and 50% for E1LN3 in univariate analysis (p=0.001/p=0.008). PD-L1 expression, pT category and age of the patients, but not CD8+ TILs were independent prognostic factors in multivariate analysis (HR=2.265, p=0.013 for SP142; HR=2.323, p=0.014 for E1LN3). PD-L1 expression was an independent predictor of shorter tumor related survival in pulmonary SqCC across all stages. The homogeneity of PD-L1 expression in "no" or "high" staining tumors across different cores and primary versus LN metastases indicates a valid assessment on small tissue samples and LN-metastases.

The relationship of p53 immunostaining to survival in carcinoma of the lung

The Potential for Serum P53 to Predict the Response to Chemotherapy of Patients with Gastric Cancer

Nuclear immunoreaction of p53 as related to prognosis of breast cancer

[Clinical Significance of Mutant P53 Protein Expression in Lung Adenocarcinoma].

The Clinical Significance of Detection of P53 Gene Mutation in Patients with Lung Cancer

The Expressions and Significances of Ki67,p53 and P-glycoprotein in Lung Squamous Cell Carcinomas and Adenocarcinomas

Immunohistochemistry of p53 surrogates TP53 mutation as an accurate predictor for early-relapse of surgically resected stage I-III lung adenocarcinoma

Relationship between expression of multidrug resistance protein,PCNA and p53 and its significance in patients with non-small cell lung cancer

Expression and Clinical Significance of Survivin and Its Correlation with P53 in Lung Squamous Cell Cacinomas and Adenocarcinomas

[The Expression of P53, Cyclin D1 and PCNA in Non-Small Cell Lung Cancer].

Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors

[Preliminary Study on Relationship among Apoptosis and Related Gene, Prognosis of Lung Cancer].

P53 Protein Expression Levels in Stage I Breast Cancer and Its Relationship to Clinico - Pathologic Parameters

Association of p53/p21 expression and cigarette smoking with tumor progression and poor prognosis in non-small cell lung cancer patients.

The Complete Loss of p53 Expression Uniquely Predicts Worse Prognosis in Colorectal Cancer

P53 Immunohistochemical Scoring: an Independent Prognostic Marker for Patients after Hepatocellular Carcinoma Resection

Significance of human papillomavirus 16/18 infection in association with p53 mutation in lung carcinomas.

Clinical Significance of P53 Expression in Colorectal Cancer Patients

P2.01-052 High PD-L1 Expression is Associated with Worse Prognosis in Primary Resected Squamous Cell Carcinomas of the Lung

Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma

Expression and Significance of P16,p21 and P53 Proteins in Lung Carcinoma